302 related articles for article (PubMed ID: 26210131)
21. The management of pulmonary hypertension in children.
Haworth SG
Arch Dis Child; 2008 Jul; 93(7):620-5. PubMed ID: 18381346
[TBL] [Abstract][Full Text] [Related]
22. Serum markers in systemic sclerosis with cardiac involvement.
Gokcen N
Clin Rheumatol; 2023 Oct; 42(10):2577-2588. PubMed ID: 37335406
[TBL] [Abstract][Full Text] [Related]
23. Systemic Sclerosis-Associated Pulmonary Hypertension: Spectrum and Impact.
Naranjo M; Hassoun PM
Diagnostics (Basel); 2021 May; 11(5):. PubMed ID: 34065226
[TBL] [Abstract][Full Text] [Related]
24. Screening strategies for pulmonary arterial hypertension.
Kiely DG; Lawrie A; Humbert M
Eur Heart J Suppl; 2019 Dec; 21(Suppl K):K9-K20. PubMed ID: 31857796
[TBL] [Abstract][Full Text] [Related]
25. Multifactorial Pulmonary Hypertension in Systemic Sclerosis.
Hussain H; Espinosa R; Chittivelu S
Cureus; 2020 Jul; 12(7):e9144. PubMed ID: 32670734
[TBL] [Abstract][Full Text] [Related]
26. The molecular targets of approved treatments for pulmonary arterial hypertension.
Humbert M; Ghofrani HA
Thorax; 2016 Jan; 71(1):73-83. PubMed ID: 26219978
[TBL] [Abstract][Full Text] [Related]
27. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F
Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
[TBL] [Abstract][Full Text] [Related]
28. Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH).
Sobanski V; Launay D; Hachulla E; Humbert M
Curr Rheumatol Rep; 2016 Feb; 18(2):10. PubMed ID: 26841964
[TBL] [Abstract][Full Text] [Related]
29. Survival in systemic sclerosis-pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry.
Hinchcliff M; Khanna S; Hsu VM; Lee J; Almagor O; Chang RW; Steen V; Chung L;
Semin Arthritis Rheum; 2015 Dec; 45(3):309-14. PubMed ID: 26210782
[TBL] [Abstract][Full Text] [Related]
30. Circulating Aldosterone Levels and Disease Severity in Pulmonary Arterial Hypertension.
Safdar Z; Thakur A; Singh S; Ji Y; Guffey D; Minard CG; Entman ML
J Pulm Respir Med; 2015 Oct; 5(5):. PubMed ID: 27170847
[TBL] [Abstract][Full Text] [Related]
31. Molecular Mechanisms of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension.
Leopold JA; Maron BA
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213345
[TBL] [Abstract][Full Text] [Related]
32. Right Ventricular Functional Reserve in Pulmonary Arterial Hypertension.
Hsu S; Houston BA; Tampakakis E; Bacher AC; Rhodes PS; Mathai SC; Damico RL; Kolb TM; Hummers LK; Shah AA; McMahan Z; Corona-Villalobos CP; Zimmerman SL; Wigley FM; Hassoun PM; Kass DA; Tedford RJ
Circulation; 2016 Jun; 133(24):2413-22. PubMed ID: 27169739
[TBL] [Abstract][Full Text] [Related]
33. Where do we go from here? Reappraising the data on anticoagulation in pulmonary arterial hypertension.
Cirulis MM; Ryan JJ
J Thorac Dis; 2016 May; 8(5):E298-304. PubMed ID: 27162687
[TBL] [Abstract][Full Text] [Related]
34. Update in pulmonary arterial hypertension.
Mejía Chew CR; Alcolea Batres S; Ríos Blanco JJ
Rev Clin Esp (Barc); 2016 Nov; 216(8):436-444. PubMed ID: 27156166
[TBL] [Abstract][Full Text] [Related]
35. A right ventricular diastolic impairment is common in systemic sclerosis and is associated with other target-organ damage.
Meune C; Khanna D; Aboulhosn J; Avouac J; Kahan A; Furst DE; Allanore Y
Semin Arthritis Rheum; 2016 Feb; 45(4):439-45. PubMed ID: 26272194
[TBL] [Abstract][Full Text] [Related]
36. Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction.
Raghu G; Nathan SD; Behr J; Brown KK; Egan JJ; Kawut SM; Flaherty KR; Martinez FJ; Wells AU; Shao L; Zhou H; Henig N; Szwarcberg J; Gillies H; Montgomery AB; O'Riordan TG
Eur Respir J; 2015 Nov; 46(5):1370-7. PubMed ID: 26250495
[TBL] [Abstract][Full Text] [Related]
37. The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study.
Thakkar V; Stevens W; Prior D; Rabusa C; Sahhar J; Walker JG; Roddy J; Lester S; Rischmueller M; Zochling J; Nash P; Gabbay E; Youssef P; Proudman SM; Nikpour M
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):129-136. PubMed ID: 27214686
[TBL] [Abstract][Full Text] [Related]
38. Carrier free dry powder formulation of sildenafil for potential application in pulmonary arterial hypertension.
Ghanbarzadeh S; Saeeneya Y; Valizadeh H; Nokhodchi A; Hamishehkar H
Pharmazie; 2016 Apr; 71(4):181-4. PubMed ID: 27209696
[TBL] [Abstract][Full Text] [Related]
39. Case report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat.
Poch DS
BMC Pulm Med; 2016 May; 16(1):82. PubMed ID: 27193179
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of Anxiety and Depression in Pulmonary Hypertension and Changes during Therapy.
Somaini G; Hasler ED; Saxer S; Huber LC; Lichtblau M; Speich R; Bloch KE; Ulrich S
Respiration; 2016; 91(5):359-66. PubMed ID: 27189373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
